These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15562003

  • 1. RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
    Mori T, Oguro A, Ohtsu T, Nakamura Y.
    Nucleic Acids Res; 2004; 32(20):6120-8. PubMed ID: 15562003
    [Abstract] [Full Text] [Related]

  • 2. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 3. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S, Hata T.
    Vitam Horm; 2004 Aug 25; 67():19-33. PubMed ID: 15110169
    [Abstract] [Full Text] [Related]

  • 4. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I.
    J Clin Pathol; 2006 Jul 25; 59(7):716-20. PubMed ID: 16489180
    [Abstract] [Full Text] [Related]

  • 5. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
    Al-Fakhri N, Hofbauer LC, Preissner KT, Franke FE, Schoppet M.
    Thromb Haemost; 2005 Dec 25; 94(6):1335-7. PubMed ID: 16411417
    [No Abstract] [Full Text] [Related]

  • 6. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G.
    J Cell Physiol; 2006 Apr 25; 207(1):158-64. PubMed ID: 16270354
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 25; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 10. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT.
    J Rheumatol; 2005 Apr 25; 32(4):713-20. PubMed ID: 15801030
    [Abstract] [Full Text] [Related]

  • 11. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N, Tsujimura T, Ueda H, Hayashi S, Ohyama H, Okamura H, Terada N.
    Cytokine; 2005 Aug 21; 31(4):288-97. PubMed ID: 15996478
    [Abstract] [Full Text] [Related]

  • 12. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A, Fuson T, Yang X, Kays J, Moxham C, Zartler E, Chandrashekhar S, Galvin RJ.
    Bone; 2005 Feb 21; 36(2):284-91. PubMed ID: 15780954
    [Abstract] [Full Text] [Related]

  • 13. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Feb 21; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
    Ashcroft AJ, Carding SR.
    Gut; 2005 Sep 21; 54(9):1345-6. PubMed ID: 16099805
    [No Abstract] [Full Text] [Related]

  • 16. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
    Maddi A, Hai H, Ong ST, Sharp L, Harris M, Meghji S.
    Bone; 2006 Aug 21; 39(2):283-8. PubMed ID: 16567138
    [Abstract] [Full Text] [Related]

  • 17. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P.
    Arterioscler Thromb Vasc Biol; 2006 Apr 21; 26(4):857-63. PubMed ID: 16424351
    [Abstract] [Full Text] [Related]

  • 18. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand.
    Schneeweis LA, Willard D, Milla ME.
    J Biol Chem; 2005 Dec 16; 280(50):41155-64. PubMed ID: 16215261
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2006 Jan 16; 54(1):76-81. PubMed ID: 16385498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.